Alnylam Pharmaceuticals Elects Michael W. Bonney To Its Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the election of Michael W. Bonney to its Board of Directors. Mr. Bonney has served as Chief Executive Officer of Cubist Pharmaceuticals and as a member of its Board of Directors since June 2003. His experience prior to that includes leadership positions in successful biotech and pharmaceutical companies including Biogen Idec and Zeneca Pharmaceuticals (now AstraZeneca).

Help employers find you! Check out all the jobs and post your resume.